SCHEMBL1574853

SCHEMBL1574853

CN(c1ccccc1)C1CN(C(=O)Nc2ccc(Cl)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
LMNA P02545 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
TP53 P04637 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
TAS1R2 Q8TE23 1/20 0.53
EPHX2 P34913 2/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
FAAH O00519 1/20 0.47
P2RX7 Q99572 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575215 0.91 GRIN2B (0.52) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1574870 0.89 MAPT (0.49) MAPTLMNANPC1RAB9ATP53
SCHEMBL1574624 0.88 GRIN2B (0.56) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1574974 0.88 MAPT (0.52) MAPTLMNANPC1RAB9ATP53
SCHEMBL1574638 0.87 GRIN2B (0.57) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL1575141 0.86 GRIN2B (0.60) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL1575465 0.85 GRIN2B (0.61) MAPTNPC1RAB9ASMN1; SMN2TAS1R3
SCHEMBL1574610 0.84 MAPT (0.51) MAPTLMNANPC1RAB9ATP53
SCHEMBL1573945 0.84 TAS1R3 (0.54) MAPTLMNANPC1RAB9ATP53
SCHEMBL1574526 0.82 KDM4E (0.48) MAPTNPC1RAB9ATP53NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885LMNA 1076/4885NPC1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.